Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + XELOX + Bevacizumab in 1L MSS mCRC
NCT06282445Phase 2Recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in colorectal cancer (metastatic) (mCRC), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Started Mar 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06282445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282445.